BHV-1400 / Biohaven - LARVOL DELTA

Study of BHV-1400 in IgA Nephropathy (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Biohaven Therapeutics Ltd. | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Glomerulonephritis • IgA Nephropathy • Renal Disease

Study of BHV-1400 in IgA Nephropathy (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Biohaven Therapeutics Ltd.

Biomarker • New P1 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments (PRNewswire) - "Expected Upcoming Milestones:...MoDE Platform: (i) IgG MoDE Degraders (1300/1310): BHV-1300 Phase 1 with the optimized subcutaneous formulation completing in 1H 2025. Expect to initiate Phase 1b study in Graves' disease in mid-2025, and additional programs in rheumatoid arthritis and myasthenia gravis continue to be pursued; (ii) Phase 1 studies with BHV-1400 and BHV-1600 expected to be completed in 1H 2025."

New P1 trial • Trial status • Grave’s Disease • Myasthenia Gravis • Rheumatoid Arthritis

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results (PRNewswire) - "IgG MoDE Degraders (1300/1310): BHV-1300 Phase 1 with the optimized subcutaneous formulation completing in 1H 2025. BHV-1310 completion of preclinical testing prior to anticipated FIH study initiating 1H 2025...Phase 1 with BHV-1400 and BHV-1600 expected to be completed in 1H 2025...Kv7 Activator (BHV-7000): Pivotal major depressive disorder topline results expected in 2H 2025. Focal epilepsy study topline results expected in 1H 2026."

Clinical data • Preclinical • Trial completion date • Epilepsy • IgA Nephropathy • Immunology • Major Depressive Disorder